This was a double-blind trial in adults with HbA@c @ % and @ % ( @-@ mmol/mol ) , randomized to saxagliptin ( SAXA ) ( @ mg/day ) plus dapagliflozin ( DAPA ) ( @ mg/day ; n = @ ) , or SAXA ( @ mg/day ) and placebo ( n = @ ) , or DAPA ( @ mg/day ) and placebo ( n = @ ) on background metformin extended release ( MET ) @,@ mg/day .